{"pmid":32388458,"title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.","text":["Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.","Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease.","Mult Scler Relat Disord","Rejdak, Konrad","Grieb, Pawel","32388458"],"abstract":["Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease."],"journal":"Mult Scler Relat Disord","authors":["Rejdak, Konrad","Grieb, Pawel"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388458","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.msard.2020.102163","keywords":["adamantanes","amantadine","covid-19","cognitive impairment","memantine","multiple sclerosis","pd","protection","sars-cov-2"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666428892563374081,"score":9.490897,"similar":[{"pmid":32436995,"title":"The Potential of Memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.","text":["The Potential of Memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.","SARS-CoV-2 appears to have neurotropic aspects with neurotoxicity through interaction with ACE2 in the medullary brainstem, causing glutamate toxicity in the rostral ventrolateral medulla (RVLM), increased sympathetic tone, hypertension and pulmonary capillary leakage of fluid into the alveoli, resulting in acute respiratory distress syndrome (ARDS). Memantine, a moderate affinity, uncompetitive N-Methyl-D-aspartic acid (NMDA) receptor antagonist which prevents excess calcium entry into cells is commonly utilized in treating patients with Alzheimer's disease, and may inhibit the neurotoxicity induced by SARS-CoV-2 in the medullary brain stem to avoid development of ARDS. Memantine and related adamantine such as amantadine, which is utilized in Parkinson's disease and influenza, may have some anti-viral potential as well. Memantine and similar adamantines may have potential as repurposed medicines for treating Covid19 with inhibition of neurotoxicity, ARDS and viral replication, since Memantine appears to be lysosomotropic. This article is protected by copyright. All rights reserved.","J Med Virol","Brenner, Steven R","32436995"],"abstract":["SARS-CoV-2 appears to have neurotropic aspects with neurotoxicity through interaction with ACE2 in the medullary brainstem, causing glutamate toxicity in the rostral ventrolateral medulla (RVLM), increased sympathetic tone, hypertension and pulmonary capillary leakage of fluid into the alveoli, resulting in acute respiratory distress syndrome (ARDS). Memantine, a moderate affinity, uncompetitive N-Methyl-D-aspartic acid (NMDA) receptor antagonist which prevents excess calcium entry into cells is commonly utilized in treating patients with Alzheimer's disease, and may inhibit the neurotoxicity induced by SARS-CoV-2 in the medullary brain stem to avoid development of ARDS. Memantine and related adamantine such as amantadine, which is utilized in Parkinson's disease and influenza, may have some anti-viral potential as well. Memantine and similar adamantines may have potential as repurposed medicines for treating Covid19 with inhibition of neurotoxicity, ARDS and viral replication, since Memantine appears to be lysosomotropic. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Brenner, Steven R"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436995","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26030","keywords":["ards","memantine","neurotrophic","sars-cov-2","hypertension","neurotoxicity"],"e_drugs":["Memantine","Glutamic Acid","Adamantane","N-Methylaspartate","Amantadine","Calcium"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393744412672,"score":248.49971},{"pmid":32440979,"title":"Assessing disability and relapses in multiple sclerosis on tele-neurology.","text":["Assessing disability and relapses in multiple sclerosis on tele-neurology.","BACKGROUND: As a consequence of the coronavirus disease 2019 (COVID-19) pandemic, a large amount of consultations will be delivered through tele-medicine, especially for diseases causing chronic disability and requiring immunomodulatory treatments, such as multiple sclerosis (MS). METHODS: We have hereby reviewed available tools for tele-neurology examination in MS, including components of neurological examination that can be assessed through video, patient-reported outcome measures (PROMs), and digital technology. RESULTS: Overall, we have suggested a battery for assessing MS disability and relapses on tele-medicine, which brings together conventional examination, PROMs (e.g., Patient Determined Disease Steps, MS Impact Scale), and cognitive tests (Symbol Digit Modalities Test) that can be delivered remotely and in multiple languages. DISCUSSION: The use of common tools for neurological examination could improve tele-neurology practice for both general neurologists and MS specialists, and quality of care for people with MS.","Neurol Sci","Moccia, Marcello","Lanzillo, Roberta","Brescia Morra, Vincenzo","Bonavita, Simona","Tedeschi, Gioacchino","Leocani, Letizia","Lavorgna, Luigi","32440979"],"abstract":["BACKGROUND: As a consequence of the coronavirus disease 2019 (COVID-19) pandemic, a large amount of consultations will be delivered through tele-medicine, especially for diseases causing chronic disability and requiring immunomodulatory treatments, such as multiple sclerosis (MS). METHODS: We have hereby reviewed available tools for tele-neurology examination in MS, including components of neurological examination that can be assessed through video, patient-reported outcome measures (PROMs), and digital technology. RESULTS: Overall, we have suggested a battery for assessing MS disability and relapses on tele-medicine, which brings together conventional examination, PROMs (e.g., Patient Determined Disease Steps, MS Impact Scale), and cognitive tests (Symbol Digit Modalities Test) that can be delivered remotely and in multiple languages. DISCUSSION: The use of common tools for neurological examination could improve tele-neurology practice for both general neurologists and MS specialists, and quality of care for people with MS."],"journal":"Neurol Sci","authors":["Moccia, Marcello","Lanzillo, Roberta","Brescia Morra, Vincenzo","Bonavita, Simona","Tedeschi, Gioacchino","Leocani, Letizia","Lavorgna, Luigi"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440979","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s10072-020-04470-x","keywords":["covid","multiple sclerosis","tele-medicine","tele-neurology"],"topics":["Prevention"],"weight":1,"_version_":1667523504884416513,"score":216.12175},{"pmid":32299636,"pmcid":"PMC7136883","title":"Should we expect neurological symptoms in the SARS-CoV-2 epidemic?","text":["Should we expect neurological symptoms in the SARS-CoV-2 epidemic?","INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS.","Neurologia","Matias-Guiu, J","Gomez-Pinedo, U","Montero-Escribano, P","Gomez-Iglesias, P","Porta-Etessam, J","Matias-Guiu, J A","32299636"],"abstract":["INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS."],"journal":"Neurologia","authors":["Matias-Guiu, J","Gomez-Pinedo, U","Montero-Escribano, P","Gomez-Iglesias, P","Porta-Etessam, J","Matias-Guiu, J A"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299636","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.nrl.2020.03.001","keywords":["central nervous system","coronavirus","esclerosis multiple","mers-cov","mouse hepatitis virus","multiple sclerosis","neurological symptoms","sars-cov","sars-cov-2","sistema nervioso central","sintomas neurologicos","virus murino de la hepatitis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494861312001,"score":197.2787},{"pmid":32469387,"title":"Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","text":["Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae.","JAMA Neurol","Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena","32469387"],"abstract":["Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae."],"journal":"JAMA Neurol","authors":["Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469387","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1001/jamaneurol.2020.2065","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668167109909151746,"score":185.00772},{"pmid":32416028,"title":"Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2.","text":["Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2.","INTRODUCTION: Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported. The aim of this study was to perform a review to describe neurological manifestations in patients with COVID-19 and possible neuro-invasive mechanisms of Sars-CoV-2. METHODS: Pubmed, WebOfScience and Covid-dedicated databases were searched for the combination of COVID-19 terminology and neurology terminology up to May 10(th) 2020. Social media channels were followed-up between March 15(th) and May 10(th) 2020 for postings with the same scope. Neurological manifestations were extracted from the identified manuscripts and combined to provide a useful summary for the neurologist in clinical practice. RESULTS: Neurological manifestations potentially related to COVID-19 have been reported in large studies, case series and case reports and include acute cerebrovascular diseases, impaired consciousness, cranial nerve manifestations and auto-immune disorders such as Guillain-Barre Syndrome often present in patients with more severe COVID-19. Cranial nerve symptoms such as olfactory and gustatory dysfunctions are highly prevalent in patients with mild-to-moderate COVID-19 even without associated nasal symptoms and often present in an early stage of the disease. CONCLUSION: Physicians should be aware of the neurological manifestations in patients with COVID-19, especially when rapid clinical deterioration occurs. The neurological symptoms in COVID-19 patients may be due to direct viral neurological injury or indirect neuroinflammatory and autoimmune mechanisms. No antiviral treatments against the virus or vaccines for its prevention are available and the long-term consequences of the infection on human health remain uncertain especially with regards to the neurological system.","Eur J Neurol","Vonck, Kristl","Garrez, Ieme","De Herdt, Veerle","Hemelsoet, Dimitri","Laureys, Guy","Raedt, Robrecht","Boon, Paul","32416028"],"abstract":["INTRODUCTION: Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported. The aim of this study was to perform a review to describe neurological manifestations in patients with COVID-19 and possible neuro-invasive mechanisms of Sars-CoV-2. METHODS: Pubmed, WebOfScience and Covid-dedicated databases were searched for the combination of COVID-19 terminology and neurology terminology up to May 10(th) 2020. Social media channels were followed-up between March 15(th) and May 10(th) 2020 for postings with the same scope. Neurological manifestations were extracted from the identified manuscripts and combined to provide a useful summary for the neurologist in clinical practice. RESULTS: Neurological manifestations potentially related to COVID-19 have been reported in large studies, case series and case reports and include acute cerebrovascular diseases, impaired consciousness, cranial nerve manifestations and auto-immune disorders such as Guillain-Barre Syndrome often present in patients with more severe COVID-19. Cranial nerve symptoms such as olfactory and gustatory dysfunctions are highly prevalent in patients with mild-to-moderate COVID-19 even without associated nasal symptoms and often present in an early stage of the disease. CONCLUSION: Physicians should be aware of the neurological manifestations in patients with COVID-19, especially when rapid clinical deterioration occurs. The neurological symptoms in COVID-19 patients may be due to direct viral neurological injury or indirect neuroinflammatory and autoimmune mechanisms. No antiviral treatments against the virus or vaccines for its prevention are available and the long-term consequences of the infection on human health remain uncertain especially with regards to the neurological system."],"journal":"Eur J Neurol","authors":["Vonck, Kristl","Garrez, Ieme","De Herdt, Veerle","Hemelsoet, Dimitri","Laureys, Guy","Raedt, Robrecht","Boon, Paul"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416028","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ene.14329","keywords":["covid-19","cerebrovascular diseases","neuroinvasive mechanism","neurological manifestations","sars-cov-2"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1666991242683088897,"score":174.78198}]}